Welcome to our dedicated page for Genflow Biosciences news (Ticker: GENFF), a resource for investors and traders seeking the latest updates and insights on Genflow Biosciences stock.
Genflow Biosciences Plc develops gene therapies for age-related diseases, with company news centered on its SIRT6-based longevity platform and related therapeutic programs. Updates include progress in canine gene therapy work, intellectual property publications for SIRT6 applications, technology collaborations supporting delivery and genomic analysis, and engagement with animal health and biotechnology partners.
Genflow's announcements also cover operating and financial results, warrant exercises and equity issuance, total voting rights, and shareholder approvals for capital authorities. The company trades in London under GENF and on OTCQB under GENFF, and its public updates frequently use UK regulatory news channels for market disclosures.
Genflow Biosciences has announced significant strides in its pre-clinical efforts for the development of therapeutic solutions targeting age-related diseases. The company has initiated a feasibility study with Exothera S.A., a CDMO, to ensure GMP-compliant production of clinical lots. Genflow is also in the process of selecting CROs for its upcoming dog clinical trial of GF-1004. Additionally, the FDA has provided research guidance through INTERACT, advising Genflow to proceed with pilot proof-of-concept studies for GF-1002, aimed at treating Metabolic Associated Steatohepatitis (MASH). The FDA's feedback supports the continuation of toxicology and biodistribution studies, which are important for eventual clinical trials. This progress highlights Genflow's commitment to advancing its therapeutic pipeline.
Genflow Biosciences (LSE:GENF, OTCQB:GENFF), an emerging leader in longevity research, announced receiving €395,847, representing 50% of the Exofastrack research grant from the Government of Wallonia. This grant, a non-dilutive, non-reimbursable subsidy, will cover 80% of the expenses for a 3-year scientific program in collaboration with EXO Biologics. The program aims to develop exosome-based therapies targeting liver fibrosis (MASH) and Werner Syndrome. CEO Dr. Eric Leire expressed enthusiasm, emphasizing the potential for groundbreaking treatments in age-related disease prevention.
Genflow Biosciences, an emerging leader in longevity research, has announced its Annual General Meeting (AGM) scheduled for June 27, 2024, at 12 pm in London. The Notice of AGM and the 2024 Form of Proxy will soon be available on the company's website. Additionally, the company has published its Annual Report and Accounts for the year ending December 31, 2023, on the website.
Genflow Biosciences has announced the receipt of €381,434, which is 50% of a research grant from the Government of Wallonia in Belgium. This non-diluting and non-reimbursable grant will fund Genflow's sarcopenia research project over the next three years, conducted in partnership with Revatis SA. The project focuses on developing muscle progenitor cells (MPCs) loaded with Genflow's proprietary SIRT6 gene to prevent and treat sarcopenia. The remaining grant amount will be disbursed over the next two years based on submitted invoices. The goal is to enhance muscle regeneration and improve the quality of life for older adults affected by muscle loss.
Genflow Biosciences PLC disclosed a major holding by Jonathan Mark Swann, increasing the voting rights to 5.03% with 17,586,000 shares on May 9th, 2024. The London-based company received the notification on May 10th, 2024. The disclosure follows the standard TR-1 form for major holdings. The shareholder, Jonathan Mark Swann, is based in Rickmansworth, United Kingdom.
Genflow Biosciences Plc, a leader in longevity research, announces the restoration of its listing on the London Stock Exchange after publishing its FY23 Results. The Company's ordinary shares are set to be relisted, marking a significant milestone in its financial journey.
Genflow Biosciences Plc, an emerging leader in longevity research, announces its final results for the year ended 31 December 2023. The company focuses on developing therapeutic solutions for age-related diseases. Genflow is the first longevity biotechnology company listed in Europe.
Genflow Biosciences PLC announces a temporary suspension of listing due to delays in publishing its Annual Financial Report for the financial year ending on December 31, 2023. The delay is not related to the company's financial position. The listing of the company's ordinary shares on the Main Market of the London Stock Exchange will be temporarily suspended from May 1, 2024.
Genflow Biosciences PLC, a leader in longevity research, disclosed its total voting rights on April 30, 2024. The company's total issued share capital consists of 349,706,618 Ordinary Shares with no shares held in treasury, resulting in the same number of voting rights. Shareholders can use this figure to determine their disclosure obligations under the Financial Conduct Authority's rules.
Summary not available.